Correspondence 0001725160-25-000073 from Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc.
Date: April 2, 2025 · CIK: 0001725160 · Accession: 0001725160-25-000073
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286122
Letter
Document Zentalis Pharmaceuticals, Inc. 10275 Science Center Dr., Suite 200 San Diego, California 92121 April 2, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Zentalis Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 26, 2025 File No. 333-286122 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Zentalis Pharmaceuticals, Inc. (the “ Company ”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-286122) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Washington D.C. time, on April 4, 2025 or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to Nathan Ajiashvili of Latham & Watkins LLP at (212) 906-2916 and that such effectiveness also be confirmed in writing. Very truly yours, Zentalis Pharmaceuticals, Inc. By: /s/ Julie Eastland Julie Eastland President and Chief Executive Officer cc: Andrea Paul, Zentalis Pharmaceuticals, Inc. Nathan Ajiashvili, Latham & Watkins LLP Salvatore Vanchieri, Latham & Watkins LLP
Show Raw Text
CORRESP 1 filename1.htm Document Zentalis Pharmaceuticals, Inc. 10275 Science Center Dr., Suite 200 San Diego, California 92121 April 2, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Zentalis Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 26, 2025 File No. 333-286122 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Zentalis Pharmaceuticals, Inc. (the “ Company ”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-286122) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Washington D.C. time, on April 4, 2025 or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to Nathan Ajiashvili of Latham & Watkins LLP at (212) 906-2916 and that such effectiveness also be confirmed in writing. Very truly yours, Zentalis Pharmaceuticals, Inc. By: /s/ Julie Eastland Julie Eastland President and Chief Executive Officer cc: Andrea Paul, Zentalis Pharmaceuticals, Inc. Nathan Ajiashvili, Latham & Watkins LLP Salvatore Vanchieri, Latham & Watkins LLP